Temsirolimus
Pancreatic Polypeptide Tumor
University of Southern CaliforniaSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Pancreatic Polypeptide Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Emory University | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
gw786034 National Cancer Institute (NCI) | Phase 2 | B |
Capecitabine ECOG-ACRIN Cancer Research Group | Phase 2 | B |
Gefetinib National Cancer Institute (NCI) | Phase 2 | B |
View all 15 →
Same molecule, other indications
Temsirolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →